20 Aug 2013
According to news reports, the FDA has granted "breakthrough status" to Novartis' myostatin blocker bimagrumab for the potential treatment of patients with sporadic inclusion body myositis.
Call for nominations for Awards Committee Chair
30 Oct 2024
James M Tanner Award - 2025 nominations open
30 Oct 2024
Would you like to host the BSPED annual meeting?
21 Oct 2024